Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials
Liu D, Zhao H, Zhang Y, Hu J, Xu H
Published in Frontiers in Pharmacology
Methodology
Systematic review and meta-analysis of randomised placebo-controlled trials of berberine on metabolic syndrome components, with sensitivity analysis, meta-regression and publication-bias assessment
Key Findings
Berberine significantly reduced triglycerides (WMD -0.367 mmol/L) and fasting plasma glucose versus placebo, with acceptable tolerability.
Conclusions
Placebo-controlled pooling supports modest improvements across metabolic syndrome markers.
Limitations
Heterogeneous doses and durations; risk of bias in several included trials.
Supplements Studied
The results indicate that berberine significantly reduces triglycerides (TG) (WMD: -0.367 mmol/L; 95% CI: -0.560 to -0.175; p < 0.001)
Outcomes Measured
Berberine has demonstrated unique comprehensive therapeutic benefits for MetS, but its efficacy remains uncertain.
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.